Expert consensus guidelines for community pharmacists in the management of diabetic peripheral neuropathy with a combination of neurotropic B vitamins.
Thanompong SathienluckanaSirinoot PalapinyoKitiyot YotsombutEkgaluck WanothayarojPasiri SithinamsuwanNaeti SuksomboonPublished in: Journal of pharmaceutical policy and practice (2024)
This consensus guidance is for community pharmacists in diabetic peripheral neuropathy (DPN) management with a combination of neurotropic B vitamins. A multidisciplinary team including endocrinology, neurology, and pharmacy from Thailand discussed and aligned the practical scheme of DPN management in the community pharmacy setting, using the literature review and having face-to-face meeting. Five major statements have been endorsed as consensus recommendations for DPN care with strong acknowledgment. The aims of DPN management included reducing symptoms and the risk of complications, minimising adverse reactions from treatment regimens, and improving patients' knowledge and adherence to the treatment strategies. An initial screening process using a 7 items interview of Douleur Neuropathique 4 (DN4) questionnaire should be implemented to identify patients at risk of developing DPN. Subsequently, pharmacologic, and non-pharmacologic treatment should be employed based on patient-centered care. An interesting approach is combination of neurotropic B vitamins, which may be used as monotherapy or combination therapy to control DPN symptoms. The combined therapy potentially exhibits a synergistic effect and improves patient adherence. The consensus would be further considered in context of harmonisation of routine practice and country requirements.
Keyphrases
- combination therapy
- healthcare
- clinical practice
- quality improvement
- palliative care
- mental health
- type diabetes
- end stage renal disease
- newly diagnosed
- case report
- chronic kidney disease
- metabolic syndrome
- emergency department
- randomized controlled trial
- skeletal muscle
- pain management
- cross sectional
- mesenchymal stem cells
- open label
- adipose tissue
- insulin resistance
- electronic health record